🔗 Share this article

Given that America undertakes historic revisions to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots in the pandemic and has focused upon possible fatalities after Covid vaccination in her short time at the FDA.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities had intended to announce major changes to the childhood immunization program earlier this month, aligning the US with the Danish national calendar, according to reports – a major change that would put the US out of alignment with much of the international standard with insufficient data for benefit. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Dr. Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s CDER, the fifth individual to run the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a renewed priority upon dismantling already-approved vaccines at the FDA.

Høeg has frequently advocated for ending some pediatric shot schedules in the US in order to be more in line with Denmark, a country with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccination policy – usually the purview of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

The appointee has little discernible experience in medication creation, oversight or management, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in leading a major agency. She is not an expert in pharmaceutical oversight.”

Former directors of CBER would “be deeply familiar with legal statutes and the underlying principles of medication creation”, said Janet Woodcock. “Objectively, she doesn’t have the sort of resume that previous people who ran the center have had.”

This division has an enormous range of responsibilities at the FDA, she emphasized.

“Everybody just zeroes in on the innovative therapies, but the generic drug division clears numerous generic medications. There’s a biosimilars program, non-prescription drug unit and more, and all of those must be managed,” Dr. Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative element to the position, which manages more than 5,000 personnel. “It is a enormous leadership role, if you execute it properly,” the former official added.

Response and Contentious Initiatives

When asked about inquiries about Høeg’s fitness for the role and whether this appointment indicates more teamwork among agency officials on immunizations, a representative responded that the “inquiries stem from inaccurate presumptions”.

“This background matches the functions of her job,” the representative explained, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg inherits the agency head's controversial priority voucher program, a controversial expedited therapy clearance system that allegedly worried her predecessors. “By what process are these therapies being selected for this expedited pathway? Who is making the choices?” Howard questioned. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer oversight of all drugs, with the exception of vaccines.”

Established Past Work on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, history, Howard said. She authored a study using unconfirmed crowd-sourced reports to assess the incidence of myocarditis after Covid immunization. She advised the Florida chief medical officer Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the new government encompassed altering rules for new vaccines and ending “optional” vaccines, she said post-election on a online show. At the agency, Høeg has reportedly suggested preventing young men from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who starts off with her conclusions and tailors the evidence to fit the data in a highly misleading, untruthful manner,” Howard stated.

Gaining Influence and a “Push for Payback”

Dr. Høeg aligned with other skeptics, {like|